Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

Abstract

Objective:

To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.

Design:

Randomized, double-blind, placebo-controlled trial of octreotide LAR at three dose levels.

Patients:

A total of 172 adults (28 men and 144 women) with at least moderate obesity (body mass index (BMI) range 30–65 kg/m2) and evidence of insulin hypersecretion were enrolled. Patients were predominantly either Caucasian (50.0%) or African American (45.3%). The mean age (38±11 year), weight (110.7±23 kg), and BMI (39.8±6.5 kg/m2) were similar across the four treatment groups.

Measurements:

Efficacy measures included weight, BMI, fasting serum glucose; triglycerides; percentage of total body fat and abdominal fat as measured by dual-energy X-ray absorptiometry; skin fold thickness; waist-to-hip circumference; leptin; percentage of carbohydrates, fat, and protein ingested; nutritional evaluation (including dietary analysis – 3-day food record); quality of life (QoL; using the Impact of Weight on Quality of Life-Lite™); Beck Depression Inventory; and Carbohydrate Craving Questionnaire. Safety measures included medical history, vital signs, physical examinations, hematology, blood chemistries, thyroid function tests, hemoglobin A1c, gallbladder ultrasound, electrocardiograms, and adverse events.

Results:

After 6 months of treatment, patients receiving 40 or 60 mg of octreotide LAR experienced statistically significant weight loss compared to baseline, with mean differences from placebo in percent weight change of −1.98 and −1.87%, respectively. This finding was accompanied by statistically significant mean decreases in BMI compared to baseline, that is, a mean decrease of 0.73 and 0.79 kg/m2 for the 40 and 60 mg treatment arms, respectively. The observed weight loss was progressive during the 6-month treatment in the two higher dose groups. The lowest dose to reach statistical significance in weight loss after 6 months' treatment was 40 mg. Post hoc analysis revealed a 3.5–3.8% weight loss at month 6 in the two higher dose groups among Caucasian patients having insulin secretion greater than the median of the cohort, defined as CIRgp (corrected insulin response at the glucose peak) 1.43. There were no statistically significant changes in QoL scores, body fat, leptin concentration, Beck Depression Inventory, or macronutrient intake. Mean changes of blood glucose AUC0–180 min during an oral glucose tolerance test in patients taking octreotide LAR were 39–40 mg/dl h higher than those on placebo. A total of 7–21% of the patients taking octreotide LAR reached a 5% or greater decrease in body weight from Baseline, compared to 11% for the placebo group. This was not statistically significant. The most common adverse events included diarrhea, headache, cholelithiasis, nausea, and abdominal pain.

Conclusion:

Octreotide LAR given at 40 or 60 mg resulted in statistically significant weight loss. A post hoc analysis stratifying patients by race and CIRgp indicated that Caucasian patients with the greater degree of insulin hypersecretion appeared to derive the most benefit from treatment. The observed safety profile was consistent with the known effects of octreotide from previous studies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–79.

    Article  Google Scholar 

  2. Bray GA . Health hazards of obesity. Endocrinol Metab Clin NA 1996; 25: 907–919.

    Article  CAS  Google Scholar 

  3. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW . Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341: 1097–1105.

    Article  CAS  Google Scholar 

  4. Kopelman PG . Obesity as a medical problem. Nature 2000; 404: 635–643.

    Article  CAS  Google Scholar 

  5. Myers A, Rosen JC . Obesity stigmatization and coping: relation to mental health symptoms, body image, and self-esteem. Int J Obes Relat Metab Disord 1999; 23: 221–230.

    Article  CAS  Google Scholar 

  6. Bray GA, Gray DS . Treatment of obesity: an overview. Diab Metab Rev 1998; 4: 653–679.

    Article  Google Scholar 

  7. Bray GA, Greenway FL . Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805–875.

    Article  CAS  Google Scholar 

  8. Consensus development conference panel, NIH Conference. Gastrointestinal surgery for severe obesity. Ann Int Med 1991; 115: 956–961.

  9. Lustig RH . The neuroendocrinology of obesity. Endocrinol Metab Clin NA 2001; 30: 765–785.

    Article  CAS  Google Scholar 

  10. Sigal RJ, El-Hashimy M, Martin BC . Acute post-challenge hyperinsulinemia predicts weight gain. Diabetes 1997; 46: 1025–1029.

    Article  CAS  Google Scholar 

  11. Meistas MT, Margolis S, Kowarski AA . Hyperinsulinemia of obesity is due to decreased clearance of insulin. Am J Physiol 1983; 245: E155–E159.

    CAS  PubMed  Google Scholar 

  12. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G . Insulin resistance and hypersecretion in obesity. European group for the study of insulin resistance (EGIR). J Clin Invest 1997; 100: 1166–1173.

    Article  CAS  Google Scholar 

  13. Lustig RH . Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist 2002; 12: 210–217.

    Article  Google Scholar 

  14. Gilon P, Henquin JC . Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function. Endocrine Rev 2001; 22: 565–604.

    CAS  Google Scholar 

  15. Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H . Glucose intolerance and insulin release, a mathematical approach. 1. Assay of the beta cell response after glucose loading. Diabetes 1976; 25: 241–244.

    Article  CAS  Google Scholar 

  16. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ . Drug therapy: octreotide. N Engl J Med 1996; 334: 246–254.

    Article  CAS  Google Scholar 

  17. Krentz AJ, MacDonald LM, Schade DS . Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994; 43: 24–31.

    Article  CAS  Google Scholar 

  18. Haqq AM, Stadler DD, Rosenfeld RG, Pratt KL, Weigle DS, Frayo FS et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children in Prader–Willi syndrome. J Clin Endocrinol Metab 2003; 88: 3573–3576.

    Article  CAS  Google Scholar 

  19. Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K et al. Hypothalamic obesity in children caused by cranial insult: altered glucose and insulin dynamics, and reversal by a somatostatin agonist. J Pediatr 1999; 135: 162–168.

    Article  CAS  Google Scholar 

  20. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003; 88: 2586–2592.

    Article  CAS  Google Scholar 

  21. Velasquez-Mieyer PA, Cowan PA, Arheart KL, Buffington CK, Spencer KA, Connelly BE et al. Suppression of insulin secretion promotes weight loss and alters macronutrient preference in a subset of obese adults. Int J Obes Relat Metab Disord 2003; 27: 219–226.

    Article  CAS  Google Scholar 

  22. Declaration of Helsinki. Recommendation guiding medical physicians in biomedical research involving human subjects. Republic of South Africa Revision, October 1996.

  23. International Conference on Harmonization (ICH). Guideline for good clinical practice. As part of the ICH Harmonized Tripartite Guideline (European Union, Japan, and USA). ICH Harmonized Tripartite Guideline, 1996.

  24. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR . Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102–111.

    Article  CAS  Google Scholar 

  25. Rom DM, Costello RJ, Connell LT . On closed test procedures for dose–response analysis. Stat Med 1994; 13: 1583–1596.

    Article  CAS  Google Scholar 

  26. Tukey JW, Ciminera JL, Heyse JP . Testing the statistical certainty of a response with increasing doses of a compound. Biometrics 1985; 41: 295–301.

    Article  CAS  Google Scholar 

  27. Preeyasombat C, Bacchetti P, Lazar AA, Lustig RH . Racial and etiopathologic dichotomies in insulin hypersecretion and resistance in obese children. J Pediatr 2005; 146: 474–481.

    Article  CAS  Google Scholar 

  28. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, Lustig RH, Cashion AK, Burghen GA . Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance testing in obese subjects. Int J Obes Relat Metab Disord 2003; 27: 1359–1364.

    Article  CAS  Google Scholar 

  29. Lustig RH . Autonomic dysfunction of the β-cell and the pathogenesis of obesity. Rev Endocrinol Metab Dis 2003; 4: 23–32.

    Article  CAS  Google Scholar 

  30. Velasquez-Mieyer PA, Umpierrez GE, Lustig RH, Cashion AK, Cowan PA, Christensen M et al. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disord 2004; 28: 1–4.

    Article  Google Scholar 

  31. Gower BA, Granger WM, Franklin F, Shewchuk RM, Goran MI . Contribution of insulin secretion and clearance to glucose-induced insulin concentration in African-American and Caucasian children. J Clin Endocrinol Metab 2002; 87: 2218–2224.

    Article  CAS  Google Scholar 

  32. Jiang Z, Srinivasan SR, Radkakrishnamurthy B, Dalferes ER, Berenson GS . Racial (black–white) differences in insulin secretion and clearance in adolescents: the Bogalusa Heart Study. Pediatrics 1996; 97: 357–360.

    CAS  Google Scholar 

  33. Yanovski JA, Yanovski SZ, Filmer KM, Hubbard VS, Avila N, Lewis B et al. Differences in body composition of black and white girls. Am J Clin Nutr 1996; 64: 833–839.

    Article  CAS  Google Scholar 

  34. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Int Med 1992; 117: 711–718.

    Article  CAS  Google Scholar 

  35. Moschetta A, Stolk MF, Rehfeld JF, Portincasa P, Slee PH, Koppeschaar HP et al. Severe impairment of postprandial cholecystokinin release and gallbladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001; 15: 181–185.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R H Lustig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lustig, R., Greenway, F., Velasquez-Mieyer, P. et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes 30, 331–341 (2006). https://doi.org/10.1038/sj.ijo.0803074

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803074

Keywords

This article is cited by

Search

Quick links